March 3, 2026Open Access

Advancing precision medicine in human epidermal growth factor receptor 2 negative gastric cancer: Insights from a novel nomogram for immunochemotherapy prognosis

Key Points

Overall survival is better predicted using a novel nomogram model integrating key biomarkers and clinical factors.
The nomogram incorporates metrics like programmed death ligand 1 expression and tumor-node-metastasis stage for accurate assessments.
Assessment using a nomogram demonstrates significant applicability in guiding immunochemotherapy treatments for gastric cancer patients.
Highlights the need for personalized approaches in managing HER2-negative gastric cancer, emphasizing the model's potential in clinical practice.

Abstract

Gastric cancer poses a significant global health burden, particularly in advanced human epidermal growth factor receptor 2-negative cases where prognosis remains poor despite advances in immunochemotherapy. The recent study by Yao et al introduces a nomogram model integrating programmed death ligand 1 expression, microsatellite status, tumor-node-metastasis stage, tumor differentiation, neutrophil-to-lymphocyte ratio, and C-reactive protein-albumin-lymphocyte index to predict progression-free and overall survival. This letter discusses the model's strengths, limitations, and its alignment with recent developments in biomarkers and therapies, emphasizing its potential for personalized medicine.

Read Full Paperexternally

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Journals

World Journal of Gastrointestinal Oncology

Institutions

Utkal University

References and Citations

Add This Paper to Your Research Feed

Any time a new paper drops it will be there.